TEI Biosciences gets FDA nod
TEI Biosciences Inc. said its SurgiMend product can now be used in wider applications for soft-tissue reconstruction after the Food and Drug Administration cleared the product for additional use.
The Boston company is developing novel biologic products for a broad spectrum of soft tissue repair.
Its SurgiMend Collagen Matrix for Soft Tissue Reconstruction product had been previously cleared for hernia repair and muscle flap reinforcement indications, the company said.
TEI announced today that it has launched SurgiMend for expanded use in plastic and reconstructive surgery, including breast reconstruction, and for tendon augmentation.
In a statement, TEI chairman, president, and chief executive Yiannis Monovoukas noted that SurgiMend "provides an opportunity for hospitals to cover a broad range of applications with a single biologic device at a single price point."
(By Chris Reidy, Globe staff)
